Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.67 USD
+0.73 (14.78%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.69 +0.02 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AQST 5.67 +0.73(14.78%)
Will AQST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
Other News for AQST
12 Health Care Stocks Moving In Friday's Intraday Session
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
Is AQST gaining bullish strength? 1,2,3 Pullback Bullish shows up after gaining 2.28%
AQST falls 0.82% on September 17, leaving the technical picture intact
AQST falls 5.25% on September 16, leaving the technical picture intact